JP2023055871A5 - - Google Patents

Download PDF

Info

Publication number
JP2023055871A5
JP2023055871A5 JP2023014793A JP2023014793A JP2023055871A5 JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5 JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
composition
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023014793A
Other languages
English (en)
Japanese (ja)
Other versions
JP7580506B2 (ja
JP2023055871A (ja
Filing date
Publication date
Priority claimed from JP2020166883A external-priority patent/JP2021008487A/ja
Application filed filed Critical
Publication of JP2023055871A publication Critical patent/JP2023055871A/ja
Publication of JP2023055871A5 publication Critical patent/JP2023055871A5/ja
Priority to JP2024189529A priority Critical patent/JP2025016606A/ja
Application granted granted Critical
Publication of JP7580506B2 publication Critical patent/JP7580506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023014793A 2014-09-16 2023-02-02 抗nkg2a抗体を使用した治療計画 Active JP7580506B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024189529A JP2025016606A (ja) 2014-09-16 2024-10-29 抗nkg2a抗体を使用した治療計画

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462050948P 2014-09-16 2014-09-16
US62/050,948 2014-09-16
US201462067642P 2014-10-23 2014-10-23
US62/067,642 2014-10-23
US201462083929P 2014-11-25 2014-11-25
US62/083,929 2014-11-25
US201462093124P 2014-12-17 2014-12-17
US201462093141P 2014-12-17 2014-12-17
US62/093,124 2014-12-17
US62/093,141 2014-12-17
JP2020166883A JP2021008487A (ja) 2014-09-16 2020-10-01 抗nkg2a抗体を使用した治療計画

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020166883A Division JP2021008487A (ja) 2014-09-16 2020-10-01 抗nkg2a抗体を使用した治療計画

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024189529A Division JP2025016606A (ja) 2014-09-16 2024-10-29 抗nkg2a抗体を使用した治療計画

Publications (3)

Publication Number Publication Date
JP2023055871A JP2023055871A (ja) 2023-04-18
JP2023055871A5 true JP2023055871A5 (cg-RX-API-DMAC10.html) 2023-08-08
JP7580506B2 JP7580506B2 (ja) 2024-11-11

Family

ID=54105801

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017514485A Pending JP2017538660A (ja) 2014-09-16 2015-09-15 抗nkg2a抗体を使用した治療計画
JP2020166883A Pending JP2021008487A (ja) 2014-09-16 2020-10-01 抗nkg2a抗体を使用した治療計画
JP2023014793A Active JP7580506B2 (ja) 2014-09-16 2023-02-02 抗nkg2a抗体を使用した治療計画
JP2024189529A Pending JP2025016606A (ja) 2014-09-16 2024-10-29 抗nkg2a抗体を使用した治療計画

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017514485A Pending JP2017538660A (ja) 2014-09-16 2015-09-15 抗nkg2a抗体を使用した治療計画
JP2020166883A Pending JP2021008487A (ja) 2014-09-16 2020-10-01 抗nkg2a抗体を使用した治療計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024189529A Pending JP2025016606A (ja) 2014-09-16 2024-10-29 抗nkg2a抗体を使用した治療計画

Country Status (13)

Country Link
US (4) US10676523B2 (cg-RX-API-DMAC10.html)
EP (1) EP3193929B1 (cg-RX-API-DMAC10.html)
JP (4) JP2017538660A (cg-RX-API-DMAC10.html)
KR (2) KR20240141862A (cg-RX-API-DMAC10.html)
CN (1) CN107074950A (cg-RX-API-DMAC10.html)
AU (3) AU2015316993B2 (cg-RX-API-DMAC10.html)
DK (1) DK3193929T3 (cg-RX-API-DMAC10.html)
ES (1) ES2742456T3 (cg-RX-API-DMAC10.html)
HU (1) HUE044704T2 (cg-RX-API-DMAC10.html)
IL (1) IL250672B (cg-RX-API-DMAC10.html)
PL (1) PL3193929T3 (cg-RX-API-DMAC10.html)
SG (2) SG11201701387SA (cg-RX-API-DMAC10.html)
WO (1) WO2016041947A1 (cg-RX-API-DMAC10.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
KR20250007689A (ko) 2014-09-16 2025-01-14 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
SMT202100280T1 (it) 2016-01-21 2021-07-12 Innate Pharma Neutralizzazione delle vie inibitorie nei linfociti
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018073363A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
WO2019011852A1 (en) * 2017-07-10 2019-01-17 Innate Pharma POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
TWI924623B (zh) 2018-03-13 2026-05-11 法商天賜製藥公司 頭頸癌之治療
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
WO2019219658A1 (en) 2018-05-15 2019-11-21 Medimmune Limited Treatment of cancer
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3878869A4 (en) * 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
WO2020205440A1 (en) * 2019-03-29 2020-10-08 Dren Bio, Inc. Methods of reducing large granular lymphocyte and natural killer cell levels
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル-マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021090146A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Combination therapy for treating cancer
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
JP2023525049A (ja) * 2020-05-08 2023-06-14 シアトル・チルドレンズ・ホスピタル・ドゥーイング/ビジネス/アズ・シアトル・チルドレンズ・リサーチ・インスティテュート ナチュラルキラー細胞を標的とするキメラ抗原受容体(car)
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
CN116194125A (zh) * 2020-08-07 2023-05-30 克莱格医学有限公司 工程化改造的细胞以及工程化改造细胞的方法
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
EP4221752A4 (en) 2020-09-30 2024-12-04 Dren Bio, Inc. ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性rna
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用
CA3222040A1 (en) * 2021-06-01 2022-12-08 Les Laboratoires Servier Anti-nkg2a antibodies and compositions
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Cldn18.2及びcd3に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
WO2024150017A1 (en) 2023-01-13 2024-07-18 Akrivia Biomedics Limited Method of profiling diseases
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
GB202417285D0 (en) 2024-11-25 2025-01-08 Univ Oxford Innovation Ltd Expanded t cell population
GB202418460D0 (en) 2024-12-16 2025-01-29 Univ Oxford Innovation Ltd Multivalent binding proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
CN101107269B (zh) * 2004-12-28 2012-10-31 依奈特制药公司 抗nkg2a的单克隆抗体
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
US20110033389A1 (en) 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
MX342131B (es) * 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
RU2017105425A (ru) 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
KR20250007689A (ko) 2014-09-16 2025-01-14 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
EP3209687A1 (en) * 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
SMT202100280T1 (it) 2016-01-21 2021-07-12 Innate Pharma Neutralizzazione delle vie inibitorie nei linfociti
TWI924623B (zh) 2018-03-13 2026-05-11 法商天賜製藥公司 頭頸癌之治療
WO2019219658A1 (en) 2018-05-15 2019-11-21 Medimmune Limited Treatment of cancer

Similar Documents

Publication Publication Date Title
JP2025016606A5 (cg-RX-API-DMAC10.html)
KR101905208B1 (ko) Cd38을 특이적으로 인식하는 항체 및 보르테조밉을 함유하는 항종양 조합물
TWI436770B (zh) 包含專一性辨識cd38之抗體及阿糖胞苷(cytarabine)之抗腫瘤組合
JP6215429B2 (ja) Cd38を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ
TWI454260B (zh) 包含專一性辨識cd38之抗體及黴法蘭(melphalan)之抗腫瘤組合
JP2009518441A5 (cg-RX-API-DMAC10.html)
JP2021512107A5 (cg-RX-API-DMAC10.html)
JP2024537288A5 (cg-RX-API-DMAC10.html)
JP2023506779A5 (cg-RX-API-DMAC10.html)
HK1164154B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
HK1164165B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan